New combo therapy shows promise for Tough-to-Treat head and neck cancer

NCT ID NCT03082534

First seen Jan 29, 2026 · Last updated May 17, 2026 · Updated 11 times

Summary

This study tested a combination of two drugs, pembrolizumab and cetuximab, in 78 people with advanced head and neck cancer that had come back or spread. Participants were grouped based on whether they had tried these drugs before. The goal was to see if the combination could shrink tumors or slow the disease. This is not a cure, but aims to help control the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • UCSD Moores Cancer Center

    La Jolla, California, 92093, United States

  • University of California Los Angeles Cancer Center

    Los Angeles, California, 90095, United States

  • University of Michigan Cancer Center

    Ann Arbor, Michigan, 48109, United States

  • Washington School of Medicine Cancer Center

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.